temozolomide

[npj Systems Biology and Applications] Differential metabolism was identified in response to temozolomide at varying concentrations in both the resistant neurospheroidal and the susceptible glioblastoma cell-lines.

[Journal of Clinical Investigation] The authors focused on gliomas’ subtype harboring mutant isocitrate-dehydrogenase-1 (mIDH1), TP53 and ATRX inactivation. IDH1-R132H is a gain-of-function mutation that converts α-ketoglutarate into 2-hydroxyglutarate.

[Scientific Reports] The authors evaluated the degree of resistance to temozolomide (TMZ) treatment in 18 patient-derived glioma cells and its association with O6-methylguanine-DNA-methyltransferase and N-methylpurine-DNA-glycosylase mRNA levels.

[Novocure] Novocure announced that the Swiss Federal Office of Public Health has added Optune® in combination with temozolomide to the List of Remedies and Equipment for the treatment of patients with newly diagnosed glioblastoma, effective April 1, 2021.

[Scientific Reports] Investigators generated a CRISPR/Cas9-mediated knockout of PLEKHG5 in U251-MG glioblastoma cells and analyzed resulting changes.

[Acta Pharmacologica Sinica] The authors evaluated 4‐Methoxydalbergione (4MOD) anti-astroglioma effects on both in vitro and in vivo models. In cultured astroglioma U87 cells, 4MOD inhibited cell proliferation and induced cell apoptosis in a time- and concentration-dependent manner.